Loading
A phase 1/2 trial of Surovatamig in acute lymphoblastic leukaemia, run by AstraZeneca, now recruiting.
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia is a phase 1/2 interventional study registered as NCT06137118 by AstraZeneca, with 255 participants planned, started 2023-12-29 and due to reach its primary completion in 2028-02-11. Interventions recorded: Surovatamig.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares AstraZeneca, Acute lymphoblastic leukaemia and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/